Pharma BD Deal Intelligence
An $8.3B all-cash acquisition that made Novartis's Sandoz division the world's largest generics company by folding in Hexal and Eon Labs. The bet paid off decisively — Sandoz was later spun off at roughly $25B, tripling the value created from the combined generics platform.
Transformative generics acquisitions built Sandoz into undisputed global leader
Full analysis, sources & comparables →Novartis acquired Hexal AG and Eon Labs for EUR 5.65 billion ($8.29 billion) in an all-cash transaction, creating the world's largest generics pharmaceutical company through its Sandoz division. Hexal was Germany's No. 2 generics company with EUR 1.65 billion in 2004 sales.
Novartis AG closes acquisition/merger of Hexal AG for $8.3B, establishing strategic position and initiating integration.
Novartis acquired Hexal for $8.3B creating the world largest generics company via Sandoz, eventually spun off at ~$25B valuation in 2023.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Hexal AG (this deal) | 2002 | $8.3B | 75 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2002 deals · Novartis AG deals · Neurology deals